| 54 |
Title |
TI |
[EN] Genetically Engineered Swine Influenza Virus and Uses Thereof |
| 71/73 |
Applicant/owner |
PA |
SINAI SCHOOL MEDICINE, US
;
ST JUDE CHILDRENS RES HOSPITAL, US
;
UNITED STATED OF AMERICA AS RE, US
|
| 72 |
Inventor |
IN |
GARCIA-SASTRE ADOLFO, US
;
LAGER KELLY M, US
;
PALESE PETER, US
;
RICHT JUERGEN A, US
;
WEBBY RICHARD J, US
;
WEBSTER ROBERT G, US
|
| 22/96 |
Application date |
AD |
Jun 1, 2005 |
| 21 |
Application number |
AN |
62829205 |
|
Country of application |
AC |
US |
|
Publication date |
PUB |
Jan 8, 2009 |
33
31
32 |
Priority data |
PRC
PRN
PRD |
US
2005019382
Jun 1, 2005
|
33
31
32 |
PRC
PRN
PRD |
US
57641804
Jun 1, 2004
|
| 51 |
IPC main class |
ICM |
C12N 7/00
(2006.01)
|
| 51 |
IPC secondary class |
ICS |
A61K 39/145
(2006.01)
A61P 31/12
(2006.01)
C12N 5/10
(2006.01)
C12N 7/04
(2006.01)
|
|
IPC additional class |
ICA |
|
|
IPC index class |
ICI |
|
|
Cooperative patent classification |
CPC |
A61K 2039/5254
A61K 2039/5256
A61K 2039/544
A61K 2039/552
A61K 2039/58
A61K 39/12
A61K 39/145
A61P 31/12
A61P 31/16
C12N 2760/16034
C12N 2760/16061
C12N 2760/16121
C12N 2760/16134
C12N 2760/16151
C12N 2760/16171
C12N 7/00
|
|
MCD main class |
MCM |
C12N 7/00
(2006.01)
|
|
MCD secondary class |
MCS |
A61K 39/145
(2006.01)
A61P 31/12
(2006.01)
C12N 5/10
(2006.01)
C12N 7/04
(2006.01)
|
|
MCD additional class |
MCA |
|
| 57 |
Abstract |
AB |
[EN] The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. |
| 56 |
Cited documents identified in the search |
CT |
US000004071618A
US000004567147A
US000004659569A
US000004693981A
US000005106619A
US000005166057A
US000005766601A
US000005786199A
US000005820871A
US000005854037A
US000005866694A
US000005882650A
US000005891705A
US000006146642A
US000006162432A
US000006300090B1
US000006326151B1
US000006468544B1
US000006573079B1
US000006635246B1
US000006635416B2
US000006649372B1
US000006669943B1
US000006675591B2
US000006686190B2
US000006852522B1
US000006866853B2
US000007060430B2
US000007132271B2
US000007833774B2
US000008012490B2
US020040109877A1
US020050054074A1
US020060216701A1
US020090123495A1
US020100158942A1
US020100233785A1
|
| 56 |
Cited documents indicated by the applicant |
CT |
|
| 56 |
Cited non-patent literature identified in the search |
CTNP |
|
| 56 |
Cited non-patent literature indicated by the applicant |
CTNP |
|
|
Citing documents |
|
Determine documents
|
|
Sequence listings |
|
|
|
Search file IPC |
ICP |
A61K 39/145
A61P 31/12
C12N 5/10
C12N 7/00
C12N 7/04
|
